Dercutane

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dercutane

What is Dercutane?

Dercutane is a pharmaceutical medication containing the active substance isotretinoin, which belongs to a class of drugs known as retinoids. It is a systemic treatment, meaning it works throughout the body rather than being applied topically to the skin. This medication is primarily used for the treatment of severe forms of acne that have not responded adequately to standard treatments, such as systemic antibiotics or topical therapies.

Mechanism of Action

The active ingredient, isotretinoin, is a stereoisomer of retinoic acid. It works by targeting several factors that contribute to the development of acne. Specifically, it significantly reduces the size and activity of the sebaceous glands, which are responsible for producing oil (sebum) in the skin. By decreasing sebum production, the medication helps to inhibit the growth of bacteria that thrive in oily environments and reduces the inflammation associated with acne lesions.

Therapeutic Use

Dercutane is typically prescribed for specific dermatological conditions, including:

  • Nodular Acne: Deep, painful lumps under the skin.
  • Conglobate Acne: A severe form of inflammatory acne characterized by interconnecting abscesses.
  • Acne at Risk of Permanent Scarring: Cases where the severity of the breakouts is likely to lead to long-term skin damage.

Because it addresses the underlying biological causes of acne formation, it is often considered for patients who have exhausted other treatment options. The treatment is usually temporary but is designed to achieve long-term remission of the condition.

What side effects are possible with Dercutane?

Possible side effects and safety information

The safety profile of Dercutane (isotretinoin) is comprehensively documented in official regulatory sources, with effects classified primarily by frequency and the body system affected. The most serious safety constraint is its classification as a potent human teratogen, resulting in an extremely high risk of severe, life-threatening birth defects if used during pregnancy. Consequently, the drug is contraindicated in pregnancy and requires strict risk management programs for female patients of childbearing potential.

Adverse reactions are frequently observed in the Skin and Subcutaneous Tissue and are classified as very common. These expected effects include dry skin, cheilitis (dry lips), epistaxis (nosebleeds), and dermatitis. Musculoskeletal effects such as arthralgia (joint pain), back pain, and myalgia are also commonly reported.

Less frequently, the label documents effects across other systems, including Psychiatric Disorders (e.g., depression, suicidal ideation classified as rare) and the Gastrointestinal System (e.g., very rare reports of inflammatory bowel disease). Serious but rare reactions also include benign intracranial hypertension and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.

The regulatory label explicitly notes that some adverse effects, such as skeletal changes (hyperostosis), are associated with long-term exposure, and certain visual impairments, like a decrease in night vision, may persist after therapy is discontinued. The medicine is contraindicated in patients with hepatic impairment and concurrent use is prohibited with both tetracycline antibiotics and Vitamin A supplements.

Overdose and Emergency Response

The regulatory documentation for Dercutane (isotretinoin) defines the overdose profile based on documented clinical manifestations and regulator-mandated emergency actions.

Element Official Regulatory Statement
Documented Manifestations Acute overdose has been associated with signs such as vomiting, dizziness, ataxia, and abdominal pain. These clinical manifestations are generally reported in regulatory sources to resolve quickly without apparent residual effects, including cheilosis and facial flushing.
Life-Threatening Risk The most critical risk is the potential for severe birth defects (teratogenicity) at any dose level, including following an overdose, if the patient is pregnant.
Immediate Action Required Regulators mandate that patients seek immediate medical attention and contact a poison control center or emergency room at once.
Overdose Management Management is described as providing symptomatic and supportive treatment; no specific antidote is known.

Due to the critical teratogenic risk, patients who are capable of becoming pregnant and who present with an overdose must be evaluated for pregnancy. If pregnancy is confirmed, specialized counseling is required. Furthermore, all individuals who have experienced an overdose should not donate blood for at least one month afterward, as specified in official documentation. These mandates underline the urgency of seeking help whenever overdose is suspected.

Therapeutic Uses of Dercutane

What Dercutane is Applied in Addressing

Dercutane (isotretinoin) is commonly used for managing severe, chronic forms of acne, specifically those presenting as nodular, cystic, or conglobate manifestations. It is considered relevant in conditions characterized by periods of heightened symptoms where the acne is resistant to standard therapy with systemic antibacterials and topical treatment. Its application focuses on easing the burden of these difficult symptomatic presentations.

The primary therapeutic domains include managing noticeable discomfort and functional strain associated with severe inflammation, deep lesions, and related skin activity. When symptoms become temporarily overwhelming, it is applied when additional supportive symptom management is appropriate. The medication provides support that helps ease the overall symptom burden and contributes to improved day-to-day comfort during symptomatic periods.

An important therapeutic benefit is its role in assisting with the reduction of the risk of severe scarring and permanent skin changes associated with inflammatory acne. It may help patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.


Quick Fact: Assistance with Severe Acne Manifestations The medication is commonly used to help manage the severe inflammatory symptoms that contribute to the risk of permanent scarring, which may assist in maintaining functional stability.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Dercutane — Official Regulatory Information

Populations for whom use is allowed (as stated in label):

  • Adults and adolescents (typically ge12 years of age) with severe recalcitrant nodular acne unresponsive to conventional therapy.
  • Female patients who are of non-childbearing potential (e.g., postmenopausal).

Populations for whom use is contraindicated:

  • Pregnant women or women who may become pregnant (Pregnancy Category X).
  • Patients who are breastfeeding.
  • Patients with hepatic insufficiency, hypervitaminosis A, or excessively elevated blood lipid values (hypertriglyceridemia).
  • Patients receiving concomitant treatment with tetracyclines or those with known hypersensitivity to the medicine or its excipients.

Age-related eligibility rules:

  • Minimum Age: Indicated for patients ge12 years old.
  • Pediatric Restriction: Use is not recommended in children under 12 or for prepubertal acne, as safety and efficacy are not established.
  • Special Consideration: Treatment for patients with severe renal insufficiency may require a lower initial starting dose.

Eligibility classifications (high-level):

  • Eligibility severity classification: Contraindicated (Absolute prohibition) or Conditional (Requires mandatory compliance with restricted distribution programs, like iPLEDGE/Pregnancy Prevention Programme).

Official eligibility statements:

  • Contraindicated in pregnancy and in women who are breastfeeding.
  • Female patients of childbearing potential are eligible only if they strictly comply with all mandatory program requirements.

Connection to the overall eligibility profile: The official regulatory documents strictly define who can and cannot use the medicine by establishing absolute contraindications to prevent fetal exposure and excluding patients with specific pre-existing organ or metabolic impairments. For other eligible populations, use is strictly conditional upon the severity of the condition and compliance with mandated risk management protocols.

What should I know about interactions with other medicines?

Dercutane (isotretinoin) is associated with several important drug and product interactions that are detailed in official regulatory information.

Interactions Requiring Avoidance or Strong Caution

Tetracycline Antibiotics: Concomitant use with drugs in the tetracycline class, such as doxycycline or minocycline, is strongly advised against (or contraindicated). This combination is associated with an elevated risk of developing idiopathic intracranial hypertension (also known as pseudotumor cerebri), a serious condition involving increased pressure around the brain.

Vitamin A and Related Supplements: Due to Dercutane's chemical similarity to Vitamin A, patients must avoid taking supplements containing Vitamin A. Co-administration can lead to additive toxicity, increasing the potential for adverse effects typically associated with excessive retinoid intake.

Systemic Corticosteroids and Phenytoin: Caution is necessary if Dercutane is used concurrently with systemic corticosteroids or phenytoin (an anti-seizure medication). This caution is based on the fact that both Dercutane and these medicines are individually known to have potential effects on bone health (such as osteoporosis or osteomalacia). Although a specific interactive effect on bone loss is not fully studied, caution is advised.

Other Acne Treatments: The concurrent use of other topical or oral acne medicines should be discussed with a healthcare provider, as this may increase the risk of skin irritation.

Oral Contraceptives: A specific trial with the combination of norethindrone and ethinyl estradiol showed no clinically relevant interaction. However, patients should confirm the compatibility of Dercutane with their specific method of hormonal contraception with a healthcare professional.

Mechanism of Action

How Dercutane Works: Mechanism of Action

The mechanism of Dercutane (isotretinoin) is complex and targets the fundamental pathology by modulating gene transcription within the pilosebaceous unit. The drug's active metabolite binds to Retinoic Acid Receptors (RAR/RXR), which are nuclear transcription factors.

This interaction initiates a molecular cascade that upregulates genes regulating cell death, resulting in the apoptosis (programmed cell death) of sebocytes (oil-producing cells). This targeted cellular destruction leads directly to the atrophy (shrinkage) of the sebaceous glands themselves, causing profound sebostasis and a systemic decrease in sebum excretion.

Simultaneously, the drug modulates the differentiation pathway of follicular epithelial cells to restore the proper shedding pattern of keratinocytes. This action prevents the excessive cellular accumulation that leads to the formation of obstructive plugs within the pore. Furthermore, the mechanism directly dampens localized inflammation by inhibiting the production of key pro-inflammatory messengers, such as cytokines, contributing to the overall reduction of inflammatory signaling.

Dosage and Administration Information

Instruction Map: How to use Dercutane — Administration Guidelines

This map consolidates the instructions for the administration of Dercutane (isotretinoin).


Administration Scope

Instruction Detail
Route of Administration Oral route (capsule form).
Dosing Schedule Initial dose is 0.5 mg/kg/day. Standard range: 0.5 to 1.0 mg/kg/day. Maximum dose up to 2.0 mg/kg/day for severe cases.
Timing in relation to meals Must be taken with a meal to enhance absorption.
Preparation Requirements Capsules must be swallowed whole with liquid; do not chew or crush.
Age-group administration rules Approved for non-pregnant patients 12 years of age and older. Severe renal impairment starts at a lower dose (e.g., 10 mg/day).
Missed-dose rules Skip the missed dose; do not take a double dose.
Special procedural conditions 15 to 20 week course duration. Mandatory 2-month hiatus before re-treatment. Dispensed with 30-day supply limit.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern Twice daily (divided doses); once daily is not recommended.
Dosage basis Weight-based dosage adjusted by patient response.
Use-context constraints Must be taken with food; adherence to a 30-day dispensing cycle.

Resulting Procedural Structure

Step sequence:

  • Dose Calculation: The initial and maintenance dosage is determined by weight, establishing a precise, standardized range.
  • Divided Intake: The total daily amount is divided and administered twice daily with food.
  • Duration Protocol: A fixed course of approximately 15 to 20 weeks is followed, with a 2-month non-treatment break required before considering any subsequent course.

Connection to the overall use protocol

The instructions mandate a structured, time-limited therapeutic plan anchored by precise 0.5 to 1.0 mg/kg/day weight-based dosing and a required twice-daily frequency. The requirement to take the capsule with food and the strict 30-day dispensing limit define the essential physical and procedural conditions for administration, creating a tightly controlled usage protocol.

Recent Clinical Evidence

Research evidence / Overview of studies for Dercutane

Evidence for Use in Severe, Recalcitrant Acne

Clinical evaluation of Dercutane (isotretinoin) for severe acne was evaluated in both Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that review data from multiple studies. Research has focused on patients diagnosed with severe nodular, cystic, or conglobate acne, particularly when the condition has been resistant to treatment with other standard systemic or topical therapies.

Researchers conducted studies to examine several outcomes related to the symptoms and inflammatory states that accompany severe acne. These outcomes included monitoring the number of inflammatory acne lesions and assessing severity scores using various standardized scales. Studies reported how symptoms evolved in the observed populations, noting changes measured during the short-term treatment period.

Findings describe patterns observed in the studies related to the measured outcomes for lesion counts and severity scores in the monitored populations. These research efforts contribute to the broader evidence landscape related to these disruptive, episodic manifestations. However, the evidence contributes primarily to understanding symptom patterns over the duration of the trial, and research does not determine whether an individual will respond similarly.


Study Design and Comparison Structure

Studies exploring the use of Dercutane was studied in RCTs, where the medicine was compared against other therapies or sometimes against a placebo (an inactive substance). These comparisons were used in research exploring how symptoms change over a defined time interval, typically 15 to 24 weeks.

Research has also explored the use of Network Meta-Analyses (NMA) and Systematic Reviews to consolidate findings from numerous trials. Data show patterns related to how different study regimens influenced outcomes describing episodic changes in acne severity across various population groups.

The evidence level for this primary indication is broadly categorized as High, based on the weight and type of studies available in the research literature.


Long-Term Studies and Follow-up

Studies have monitored patients beyond the initial treatment phase to assess long-term outcomes and symptom patterns after the study period. Long-term research monitors the rate of recurrence or relapse of severe acne symptoms following cessation of therapy.

However, the understanding of long-term outcomes is not fully established, particularly for periods extending beyond two years post-treatment, as long-term studies are inherently challenging to conduct.

Frequently Asked Questions (FAQ)

Common questions about Dercutane (FAQ)


Q: How long does it usually take for Dercutane to start working?

According to official product information, the therapeutic response typically begins within a treatment period of 16 to 24 weeks. The full course of treatment is generally described as lasting approximately 15 to 20 weeks.


Q: Is it normal to experience a temporary worsening of acne at the beginning of Dercutane use?

Official documents note that a temporary exacerbation of acne is a documented observation that may occur during the first few weeks of starting treatment. This change is consistent with documented clinical patterns of the medicine’s use.


Q: Are there any long-term effects associated with using Dercutane?

Official information indicates that certain adverse effects are associated with long-term exposure, such as skeletal changes (e.g., hyperostosis). Furthermore, some visual impairments like a decrease in night vision may sometimes persist after the therapy has been discontinued.


Q: Can Dercutane cause permanent changes to the skin?

Dercutane is associated with temporary skin changes like dryness and irritation during use. The official label also notes that there is an increased risk of rare but serious effects, such as hypertrophic scarring or keloids, if certain skin-smoothing cosmetic procedures are performed while the patient is using the medication.


Q: Is Dercutane known to cause changes in mood or emotional well-being?

Rare adverse reactions classified under Psychiatric Disorders have been documented, including depression and suicidal ideation. The risk management program includes monitoring for these potential effects.


Q: Can Dercutane affect vision or night sight?

Yes, official product information indicates that the medication is associated with visual disturbances, including a decrease in night vision, which may sometimes persist after treatment is completed. Dry eyes and intolerance to contact lenses are also documented effects.


Q: Are there any specific cosmetic procedures or products to avoid while taking Dercutane?

Official guidelines advise patients that they must avoid skin-smoothing cosmetic procedures, such as waxing, dermabrasion, and laser procedures, during treatment and for at least six months afterward. This is due to an increased risk of scarring and atypical wound healing.


Q: Does Dercutane interact with any common over-the-counter pain relievers?

Official labeling does not cite a specific interaction with common over-the-counter pain relievers (such as acetaminophen or ibuprofen). However, the label notes that caution is a factor when the drug is used concurrently with other drugs that may affect bone or liver health.


Q: Can vitamins or herbal supplements interfere with Dercutane?

Patients are instructed to strictly avoid taking Vitamin A supplements because this can lead to additive toxicity. The regulatory information also notes that some herbal supplements may reduce the effectiveness of hormonal birth control, which is a key precaution for women taking Dercutane.


Q: Do men who take Dercutane need to use any special precautions?

While the teratogenic risk is specific to female patients, official guidelines advise all patients, including men, to not share the medication with anyone. Additionally, men are advised to not donate blood during treatment and for a period afterward to prevent exposure to pregnant recipients.


Q: Is Dercutane used to treat any conditions other than severe acne?

Dercutane is indicated primarily for the treatment of severe recalcitrant nodular acne that has not responded to other therapies. The regulatory label does not list other approved uses for the medicine.


Q: Can Dercutane be used by people who have a history of depression?

Regulatory documents describe depression and suicidal ideation as rare potential side effects. Close monitoring by a healthcare provider is a documented factor for patients with a history of depression.


Q: Are there any specific dietary restrictions described for people using Dercutane?

The main instruction for use is that the medicine must be taken with a meal to enhance its absorption into the body. Patients must also strictly avoid taking Vitamin A supplements. Dietary restrictions outside of this are not specified in the official labeling.


Q: Why do official guidelines emphasize not donating blood while taking Dercutane?

Patients are instructed not to donate blood during treatment and for one month after stopping the medication. This precaution is mandated to prevent blood that contains the drug from being given to a pregnant female recipient, due to the severe risk of birth defects.


Q: Does Dercutane interact with alcohol consumption?

Alcohol consumption may increase the risk of elevated triglycerides and liver damage. Some regulatory documents note the importance of avoiding or restricting alcohol intake during treatment.


Q: Is the effect of Dercutane permanent after the treatment course is finished?

The drug is intended for use in the treatment of severe acne. Clinical trials document that some patients may experience an acne relapse after the treatment course is finished, which may necessitate further treatment.


Q: Why is Dercutane generally reserved for severe forms of acne?

Dercutane is reserved for severe recalcitrant nodular acne because of its high efficacy, which is balanced against its potential for significant side effects. This includes the severe risk of birth defects, which necessitates strict risk management protocols.


Q: Can Dercutane affect healing time for wounds or cuts?

Official information indicates that the drug is associated with impaired wound healing. It also carries an increased risk of scarring, specifically keloids and hypertrophic scars, if certain skin-altering procedures are performed.


Q: Are there different strengths of Dercutane available?

Yes, Dercutane capsules are typically available in several strengths to allow for flexible administration. Common strengths usually include 10 mg and 20 mg capsules.


Q: Are eye irritation or dry eyes a common side effect of Dercutane?

Yes, dry eyes and eye irritation are documented side effects of Dercutane. This is also linked to the documented visual disturbance known as intolerance to contact lenses.


Q: Are there any warnings about driving or operating machinery while taking Dercutane?

Official product information advises caution because Dercutane may cause decreased night vision, which can occur suddenly. If a patient experiences this, regulatory warnings indicate that driving or operating machinery at night is restricted.


Q: Is Dercutane used for treating acne scars?

The primary indication for Dercutane is the treatment of severe acne to prevent permanent scarring. It is not directly indicated in regulatory documents for the treatment of existing acne scars.


Q: Can Dercutane cause hair thinning or hair loss?

Yes, official product information includes hair loss (alopecia) as a documented, though uncommon, side effect of the medication.


Q: Can Dercutane affect the growth plates in younger patients?

The drug is associated with a risk of premature epiphyseal closure (a stoppage of bone growth) in adolescents. This risk is typically linked to long-term use or receiving high doses of the medication.


Q: How long after stopping Dercutane is it considered safe to become pregnant?

Due to the potential for severe birth defects, official documentation notes that female patients must continue using effective contraception for one month after stopping Dercutane. This ensures a period where the drug is fully eliminated from the body.


Q: How are the risks associated with Dercutane explained in regulatory documents?

The high risks associated with the drug are managed through an official Risk Evaluation and Mitigation Strategy (REMS) or a Pregnancy Prevention Programme (PPP). These programs mandate strict patient education, informed consent, and mandatory monthly monitoring requirements.


Q: Is it necessary to have blood tests done while using Dercutane?

Yes, regulatory requirements mandate regular blood tests for monitoring. These tests specifically check for potential effects on lipid values (cholesterol and triglycerides) and liver function, as these levels can be affected by the medication.


Q: What kind of monitoring is done for people taking Dercutane?

Monitoring involves regular blood tests to check liver function and lipid levels. It also includes a clinical assessment by a healthcare provider to check on the patient's general well-being, including mental health and any symptoms of severe side effects.


Q: What specific laboratory tests are used to monitor Dercutane use?

The monitoring typically involves performing Liver Function Tests (LFTs) to check the levels of liver enzymes (like ALT and AST). Additionally, a Lipid Panel is used to check for changes in cholesterol and triglyceride levels.


Q: What does the research say about the likelihood of acne relapse after stopping Dercutane?

Clinical studies and published research indicate that acne relapse rates can occur after treatment is completed. The rates observed vary based on the total dose received over the treatment period and other individual factors.


Q: What are the age limits for using Dercutane, according to official guidelines?

Dercutane is approved for use in non-pregnant patients who are 12 years of age and older. Use is generally not recommended in children under 12 or for pre-pubertal acne because its safety and effectiveness have not been established in these populations.


Q: Does the time of day matter when Dercutane is taken?

The official instruction is that the medicine must be taken with a meal to enhance its absorption. The total daily amount is also typically divided and administered in two divided doses.


Q: What are the regulatory requirements for pharmacy dispensing of Dercutane?

Dercutane is only dispensed by pharmacies that are enrolled in the official risk management program. Dispensing is strictly limited to a 30-day supply at a time, requiring a new prescription and adherence check for each refill.

How should Dercutane be stored and disposed of?

Storage and Disposal Requirements for Dercutane (Isotretinoin)

Official labeling mandates specific conditions for storing and disposing of Dercutane capsules.

Storage Conditions

Isotretinoin must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product requires strict protection from light and moisture. It must be kept in its original container, tightly closed, in a dry location, and must not be frozen. For safety, the medicine must be stored strictly out of the reach of children.

Disposal Instructions

Unused or expired Dercutane should be disposed of via community drug take-back programs as the preferred method. If a program is unavailable, the medicine should be mixed with an undesirable substance, placed in a sealed container, and thrown into the household trash. The medicine must not be flushed down the toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dercutane found in:

A-Z Index: